TEVA — Teva Pharmaceutical Industries Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro Cap

Annual income statement for Teva Pharmaceutical Industries, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	16,659	15,878	14,925	15,846	16,544
Cost of Revenue
Gross Profit	7,789	7,864	7,438	7,976	8,292
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	20,231	14,162	17,122	15,413	16,847
Operating Profit	-3,572	1,716	-2,197	433	-303
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4,406	658	-3,163	-624	-1,284
Provision for Income Taxes
Net Income After Taxes	-4,238	447	-2,520	-617	-1,960
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-3,991	417	-2,446	-559	-1,639
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-3,990	417	-2,446	-559	-1,639
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.356	1.42	1.02	1.35	0.795
Dividends per Share